BeyondSpring Inc. $BYSI

By Microcap Ledger desk · CIK 0001677940

Facts as of Oct 11, 2026, 08:14 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Pharmaceutical Preparations
Headquarters: Florham Park, NJ
Fiscal year end: December 31
Shares outstanding: 41,119,820 [10-Q 2026-08-14]
as of 2026-07-31

Sources: [10-K 2026-03-25]

What the company doesAI summary of filing

BeyondSpring Inc. is a clinical-stage biopharmaceutical company developing Plinabulin, a protein degradation drug candidate being tested for multiple cancer indications including chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer (NSCLC). The company does not currently generate revenue from product sales and has no approved drugs on the market. BeyondSpring relies on completing clinical trials, obtaining regulatory approvals from the FDA, NMPA (China), EMA, and other authorities, and securing additional financing to advance its pipeline and commercialize any approved products in the future. [10-K 2026-03-25]

Segments: Plinabulin for CIN (prevention of chemotherapy-induced neutropenia), Plinabulin for NSCLC (non-small cell lung cancer), SEED Targeted Protein Degradation (TPD) Platform

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	$0.00	−$3.01M	−$7.05M	$2.70M	[10-Q 2026-08-14]
FY ended Dec 2025	$0.00	−$1.01M	−$19.77M	$7.79M	[10-K 2026-03-25]
FY ended Dec 2024	$0.00	−$11.12M	−$16.44M	$2.92M	[10-K 2026-03-25]

Quarterly cash burn: −$3.52M
Cash runway Estimate: ~2.3 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2025-02-28	40,316,320	[10-K 2025-03-27]
2025-04-30	40,316,320	[10-Q 2025-05-12]
2025-07-25	40,332,320	[10-Q 2025-08-13]
2025-09-30	40,332,320	[10-Q 2025-11-12]
2026-02-27	41,119,820	[10-K 2026-03-25]
2026-04-30	41,119,820	[10-Q 2026-05-13]
2026-07-31	41,119,820	[10-Q 2026-08-14]

Shelf registration: F-3 filed 2024-06-12; declared effective 2025-08-18 [F-3 2024-06-12]

Listing status

Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-10-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-10-02	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-10-02]
2026-09-18	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-09-18]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-03-20	Huang Lan	other	260,582	—	[4 2026-05-15]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-10-06	8-K	Acquisition or disposition completed
2026-10-02	8-K	Listing notice or transfer
2026-09-29	8-K	Material agreement entered; Other events
2026-09-29	424B5	Prospectus or prospectus supplement
2026-09-18	8-K	Listing notice or transfer
2026-09-03	DEF 14A	Proxy statement
2026-08-14	13G/A	Beneficial ownership report (5%+ holder)
2026-08-14	10-Q	Quarterly report
2026-08-14	8-K	Results of operations
2026-06-29	8-K	Director or officer change
2026-06-04	8-K	Director or officer change; Regulation FD disclosure
2026-05-15	13G/A	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 08:14 AM UTC. Small caps move fast; check the latest filings.